In this retro-prospective study (IRB approval OSS.16.253), patients were invited to attend ophthalmic evaluation [2]. Incidence of NTG and life status were recorded during a follow-up extended up to December 31st, 2019. We used Kaplan-Meier survival curves (with follow-up time defined as the time from CSFs until NTG diagnosis, i.e., “exposure period”, death, or loss to follow-up, whichever came first) to describe the occurrence of NTG. We applied the log-rank test to identify risk and protective factors of NTG occurrence.

Results are summarized in the supplemental flow chart (Supplementary Fig. 1). Three patients died (one in the NGT group and two in non-NGT group), while seven patients (two NTG and five non-NTG) deteriorated cognitively (thus preventing their evaluation) during the extended follow-up. Two of the six non-NTG patients that could be re-evaluated developed NTG (Table 1) after 28 and 32 months from the original visit (9.5 and 4.0 years from CSFs, respectively) raising the number of patients with documented NTG to eleven (50% of the total cohort). Four patients were still NTG free. However, ganglion cell complex thickness, mean deviation and pattern standard deviation values, showed significant deterioration (Table 1).

Table 1 Comparison of instrumental ophthalmic data obtained at 2 time points in 6 idiopathic normal pressure hydrocephalus patients who underwent cerebrospinal fluid shunting.
Full size table

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD